Commercial Channels

Discerning how and where products are discounted is an expensive headache for manufacturers

A new, market-driven model of drug development and commercialization is appearing*

MarkMonitor updates its surveillance surveys against counterfeiting and drug diversion

Government at all levels are trying to mobilize to address the crisis

Advisory program makes data reporting more uniform

New survey finds more digitally-savvy healthcare providers, challenging reps' presentation capabilities

Marken offers tailored logistics services to research community

TGaS Advisors expands its roster of services

Good growth is occurring in the vaccine business, despite the hurdles of public perceptions and public-health funding shortfalls

Office of Prescription Drug Promotion finds little to complain about

'Average Manufacturer Price' is now a mostly settled matter

Combination expands breadth of commercialization and compliance services

List includes 21 new orphan drugs, and of the 45, 15 are cold chain products

Are hubs a help or hindrance in getting patients on therapy?

Even with legislative incentives, pharma manufacturers struggle to cost-justify pediatric innovation

Biennial survey finds growing awareness of information options by consumers

Xerox subsidiary expands its call-center operations to include specialty reimbursement services

Survey shows that most digital channels are still experiments with little oversight or follow-through

With competing products and pricing pressure, the rare disease market is starting to resemble the conventional drug market

Latest SK&A pharmacy data outlines retail channel

While the biopharma industry continues to develop better treatment options, there is a stronger focus on more intensive patient engagement